-
Bellerophon Therapeutics NASDAQ:BLPH Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system.
Location: 184 Liberty Corner Rd Ste 302, New Jersey, 07059-6868, US | Website: www.bellerophon.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.942M
Cash
4.382M
Avg Qtr Burn
-3.085M
Short % of Float
0.89%
Insider Ownership
15.03%
Institutional Own.
8.39%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INOpulse Details Interstitial lung disease, Pulmonary hypertension | Failed Discontinued | |
INOpulse Details Chronic obstructive pulmonary disease, Pulmonary hypertension, Heart disease, Heart failure | Failed Discontinued | |
INOpulse Details Sarcoidosis, Pulmonary hypertension | Failed Discontinued | |
INOpulse® Details COVID-19 | Failed Discontinued |